ABUS vs COLL: stock comparison and AI forecast
Arbutus Biopharma Corp (ABUS) and Collegium Pharmaceutical, Inc (COLL) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ABUS Arbutus Biopharma Corp
- Market Cap
- $768M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
COLL Collegium Pharmaceutical, Inc
- Market Cap
- $775M
- P/E Ratio
- 25.6x
- Size
- small-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ABUS and COLL have similar market capitalizations ($768M and $775M).
- COLL carries 5.85 times debt per unit of equity, against 0.06 times for ABUS.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ABUS | COLL |
|---|---|---|
| Market Cap | $768M | $775M |
| P/E Ratio | – | 25.59x |
| P/B Ratio | 2.97x | 2.48x |
| EPS | $-0.21 | $0.93 |
| Book Value/Share | $1.31 | $9.58 |
| Revenue/Share | $0.92 | $24.83 |
| FCF/Share | – | $10.08 |
Profitability & Margins
| Metric | ABUS | COLL |
|---|---|---|
| ROIC | 55.0% | 10.2% |
| Gross Margin | – | 60.0% |
| Operating Margin | 82.0% | 19.5% |
| EBT Margin | 84.6% | 9.6% |
| Tax Rate | 0.0% | 38.3% |
Financial Health
| Metric | ABUS | COLL |
|---|---|---|
| Current Ratio | 81.42x | 1.03x |
| Quick Ratio | – | 0.84x |
| D/E Ratio | 0.06x | 5.85x |
| Financial Leverage | 1.06x | 6.85x |
| Interest Coverage | – | 0.3x |
| Working Capital | $271M | $18M |
Cash Flow
| Metric | ABUS | COLL |
|---|---|---|
| Operating Cash Flow | -$25M | $330M |
| Free Cash Flow | – | $328M |
| Capital Spending | – | -$2M |
| OCF Growth YoY | – | 62.1% |
| FCF Growth YoY | – | 62.7% |
| FCF/Sales | – | 40.6% |
| CapEx/Sales | – | 0.2% |
Operational Efficiency
| Metric | ABUS | COLL |
|---|---|---|
| Asset Turnover | 0.66x | 0.38x |
| Receivables Turnover | 492.5x | 2.8x |
| Inventory Turnover | – | 2.9x |
| Fixed Assets Turnover | 18172.0x | 75.9x |
| Days Sales Outstanding | 1 days | 129 days |
| Days Inventory | – | 128 days |
| Payables Period | – | 10 days |
| Cash Conversion Cycle | – | 246 days |
Income Statement
| Metric | ABUS | COLL |
|---|---|---|
| Total Revenue | $182M | $808M |
| Operating Income | $149M | $157M |
| R&D Expense | $18M | – |
| SG&A Expense | – | $328M |
| Cost of Goods Sold | – | $323M |
Dividend & Shareholder Information
| Metric | ABUS | COLL |
|---|---|---|
| Shares Outstanding | 198M | 33M |
| EPS Growth | – | -44.6% |
ABUS vs COLL: stock comparison and AI forecast
Which is bigger, ABUS or COLL?
ABUS and COLL have similar market capitalizations ($768M and $775M).
Which one does Intratio's AI model rank higher, ABUS or COLL?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.